Raymond ScottTurnerMDPhD

Neuroimaging, Neurodegenerative, Dementia & Geriatrics

Vice Chair for Clinical Research, Professor of Neurology, and Director of the Memory Disorders Program at Georgetown University

Join to view full profile

Dr. Turner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Turner's full profile

Already have an account?

Office
4000 Reservoir Road, NW
Suite 177, Building D
Washington, DC 20057
Phone+1 202-687-7337

Fax+1 202-784-4332
Is this information wrong?

Summary

The mission of the Georgetown University Memory Disorders Program is to prevent and treat Alzheimer's disease and related dementias by conducting innovative research, educating and training healthcare professionals and the public on research advances, and offering state-of-the-art clinical care.

Education & Training

Penn MedicineBehavioral Neurology, 1992 - 1995
University of Pennsylvania Health SystemResidency, Neurology, 1989 - 1992
University of Pennsylvania Health SystemInternship, Internal Medicine, 1988 - 1989
Emory University School of MedicineClass of 1988, M.D.
Emory UniversityPh.D., Pharmacology, 1979 - 1984
Clemson UniversityB.S., Microbiology, Molecular Biology, with Honor, 1975 - 1979

Certifications & Licensure

VA State Medical License 2019 - 2024
DC State Medical License 2008 - 2024
MI State Medical License 1995 - 2011
PA State Medical License 1990 - 1996
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Fellow American Academy of Neurology, 2019
Fellow (elected) American Neurological Association, 2006
Paul Beeson Career Development Award in Aging Research American Federation for Aging Research, 1998-2001
Postdoctoral Research Fellowship for Physician-Scientists Howard Hughes Medical Institute, 1992-1995
Join now to see all

Clinical Trials

Memory Improvement Through Nicotine Dosing (MIND) Study Start of enrollment: 2017 Jan 13
Active, not recruiting
Phase 2
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Start of enrollment: 2019 Mar 27
Active, not recruiting
Phase 3
Metformin in Alzheimer's Dementia Prevention Start of enrollment: 2021 Mar 22
Recruiting
Phase 2, Phase 3
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) Start of enrollment: 2021 Jul 22
Active, not recruiting
Phase 1, Phase 2
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Start of enrollment: 2020 Jul 14
Recruiting
Phase 3
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease Start of enrollment: 2021 Jan 22
Active, not recruiting
Phase 2
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease Start of enrollment: 2021 Jan 06
Active, not recruiting
Phase 2
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD Start of enrollment: 2021 Nov 15
Recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Start of enrollment: 2023 Jun 28
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
Turner, R., Turner, R., Marie-Emmanuelle Riviere, Jessica B Langbaum, Juha O Rinne, Yihan Sui, Pilar Cazorla, Javier Ricart, Kathleen Meneses, Angelika Caputo, Pierre ...> ;Alzheimer's & Dementia. 2024 Mar 1
Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?
Turner, R.> ;Neurology. 2024 Feb 27
Resveratrol differentially affects MMP-9 release from neurons and glia; implications for therapeutic efficacy.
Turner, R., Matthew Amontree, Matthew Nelson, Lara Stefansson, Daniel Pak, Kathleen Maguire-Zeiss, R Scott Turner, Katherine Conant> ;Journal of Neurochemistry. 2024 Jan 1
An explainable machine learning model of cognitive decline derived from speech.
Turner, R., Turner, R., Chelsea Chandler, Catherine Diaz-Asper, Raymond S Turner, Brigid Reynolds, Brita Elvevåg> ;Alzheimer's & Dementia. 2023 Dec 27
1 citations
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) coh...
Turner, R., Polsinelli, A., Wonderlin, R., Hammers, D., Garcia, A., Eloyan, A., Taurone, A., Thangarajah, M., Beckett, L., Gao, S., Wang, S., Kirby, K., Logan, P., Ais...> ;Alzheimer's & Dementia. 2023 Nov 1
Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.
Turner, R., Turner, R., Kelly N H Nudelman, Trever Jackson, Malia Rumbaugh, Ani Eloyan, Marco Abreu, Jeffrey L Dage, Casey Snoddy, Kelley M Faber, Tatiana Foroud, Dust...> ;Alzheimer's & Dementia. 2023 Nov 1
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Ear...
Turner, R., Eloyan, A., Thangarajah, M., An, N., Borowski, B., Reddy, A., Aisen, P., Dage, J., Foroud, T., Ghetti, B., Griffin, P., Hammers, D., Iaccarino, L., Jack, C...> ;Alzheimer's & Dementia. 2023 Nov 1
1 citations
Learning slopes in early-onset Alzheimer's disease.
Turner, R., Dustin B Hammers, Sára Nemes, Taylor Diedrich, Ani Eloyan, Kala Kirby, Paul Aisen, Joel Kramer, Kelly Nudelman, Tatiana Foroud, Malia Rumbaugh, Alireza Atr...> ;Alzheimer's & Dementia. 2023 Nov 1
2 citations
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.
Mark Monane, Kim G Johnson, B Joy Snider, Raymond S Turner, Jonathan D Drake, Demetrius M Maraganore, James L Bicksel, Daniel H Jacobs, Julia L Ortega, Joni Henderson,...> ;Annals of Clinical and Translational Neurology. 2023 Oct 1
1 citations
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
Sára Nemes, Paige E Logan, Mohit K Manchella, Nidhi S Mundada, Renaud La Joie, Angelina J Polsinelli, Dustin B Hammers, Robert A Koeppe, Tatiana M Foroud, Kelly N Nude...> ;Alzheimer's & Dementia. 2023 Nov 1
1 citations
Matrix disequilibrium in Alzheimer's disease and conditions that increase Alzheimer's disease risk.
Matthew Amontree, Samantha Deasy, R Scott Turner, Katherine Conant> ;Frontiers in Neuroscience. 2023 Jan 1
Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease.
Max Stevenson, Rency Varghese, Michaeline L Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R Scott Turner, Charbel Moussa> ;Journal of Neuroinflammation. 2023 May 16
2 citations
CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice.
Griffin A Greco, Mitchell Rock, Matthew Amontree, Maria Fe Lanfranco, Holly Korthas, Sung Hyeok Hong, R Scott Turner, G William Rebeck, Katherine Conant> ;Neurobiology of Disease. 2023 Apr 1
2 citations
Increasing access to cognitive screening in the elderly: Applying natural language processing methods to speech collected over the telephone.
Catherine Diaz-Asper, Chelsea Chandler, Raymond S Turner, Brigid Reynolds, Brita Elvevåg> ;Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 2022 Nov 1
6 citations
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.
Fernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, Barbara Wilmarth, R Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa> ;Alzheimer's & Dementia. 2022 Jan 1
37 citations
Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
Charles G Withington, R Scott Turner> ;Frontiers in Neurology. 2022 Jan 1
Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV.
Amanda Blair Spence, Chenglong Liu, Leah Rubin, Bradley Aouizerat, David Eugene Vance, Hector Bolivar, Cecile Delille Lahiri, Adaora A Adimora, Kathleen Weber, Deborah...> ;AIDS Research and Human Retroviruses. 2022 Jul 1
Corrigendum: A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease.
Ibrahim Almubark, Lin-Ching Chang, Kyle F Shattuck, Thanh Nguyen, Raymond Scott Turner, Xiong Jiang> ;Frontiers in Aging Neuroscience. 2022 Jan 1
2 citations
Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer's disease.
Xiong Jiang, James H. Howard, G. William Rebeck, Raymond Scott Turner> ;Plos One. 2021 Jun 14
5 citations
Acceptability of collecting speech samples from the elderly via the telephone.
Catherine Diaz-Asper, Chelsea Chandler, R. Scott Turner, Brigid Reynolds, Brita Elvevåg, Turner, R.> ;Digital Health. 2021 Apr 17
20 citations
Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer's Disease.
Aida Adlimoghaddam, Gary G Odero, Gordon W. Glazner, R. Scott Turner, Benedict C. Albensi> ;Aging and Disease. 2021 Apr 1
7 citations
Low CD4+ cell count nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV.
Fan Nils Yang, Margarita Bronshteyn, Sarah A. Flowers, Matthew S. Dawson, Princy Kumar, George William Rebeck, Raymond Scott Turner, David Moore, Ronald J. Ellis, Xion...> ;AIDS. 2021 Apr 1
9 citations
Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout:
Shana D. Stites, R. Scott Turner, Jeanine Gill, Anna Gurian, Jason Karlawish, Joshua D. Grill> ;Clinical Trials. 2021 Jan 10
8 citations
A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease.
Ibrahim Almubark, Lin-Ching Chang, Kyle F. Shattuck, Thanh Nguyen, Raymond Scott Turner, Xiong Jiang> ;Frontiers in Aging Neuroscience. 2020 Dec 3
29 citations
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
Nicolai Franzmeier, M. Suárez-Calvet, Lukas Frontzkowski, Annah M. Moore, Timothy J. Hohman, Estrella Morenas-Rodríguez, Brigitte Nuscher, Leslie M. Shaw, John Q. Troj...> ;Molecular Neurodegeneration. 2020 Oct 8
Join now to see all

Books/Book Chapters

Neuropsychology of Cortical Dementias
Chapter: Primary Progressive Aphasia
Page 265 - 284Friedman R, Long S, Turner RSEditors: Noggle CA, Dean RS.Springer, Inc., New York2015
Alzheimer's Disease. Targets for New Clinical Diagnostic and Therapeutic Strategies
Chapter: Alzheimer's Disease: Clinical Aspects
Page 211 - 230Turner RSEditors: Wegrzyn D, Rudolph AS.CRC Press, Boca Raton2012
Alzheimer's Disease: New Advances
Chapter: Modulation of neuronal APP metabolism by X11alpha/mint-1/APBA1
Page 385 - 392Saluja I, Saunders TL, Turner RSEditors: Iqbal K, Winblad B, Avila J.Medimond, Bologna2007
Neurogenetics: Scientific and Clinical Advances
Chapter: Alzheimer's DIsease
Page 643 - 661Turner RSEditors: Lynch D.Taylor and Francis, New York2006
Handbook of Dementia. Psychological, Neurological, and Psychiatric Perspectives
Chapter: Neurologic Aspects of Alzheimer's Disease
Page 1 - 24Turner RSEditors: Lichtenberg PA, Murman DL, Mellow AM.Wiley, Inc., Hoboken2003
Neurology Pearls of Wisdom
Chapter: Behavioral Neurology
Page 21 - 30Heidebrink JL, Turner RSEditors: Labanowski M.Boston Medical Publishing, BostonEdition 2,2001
Alzheimer's Disease and Related Disorders. Etiology, Pathogenesis and Therapeutics
Chapter: X11 modulation of beta-amyloid precursor protein cellular stabilization and reduction of amyloid beta-protein secretion
Page 397 - 404Levy E, Sastre M, Turner RSEditors: Iqbal K, Swaab DF, Winblad B, Wisneiwski HM.Wiley, Chichester1999
Neurology Pearls of Wisdom
Chapter: Behavioral Neurology
Page 21 - 28Turner RS, Heidebrink JLEditors: Labanowski M.Boston Medical Publishing, BostonEdition 1,1998
Advances in Inflammation Research
Chapter: Phospholipid/Calcium-dependent protein kinase (protein kinase C) as effector and modulator for membrane signals: an overview
Page 63 - 71Turner RS, Kuo JFEditors: Russo-Marie F, Menciahuerta JM, Chignard M.Raven, New York1986
Phospholipids and Cellular Regulation
Chapter: Phospholipid-Sensitive Calcium-Dependent Protein Kinase (Protein Kinase C): The Enzyme, Substrates, and Regulation
Page 75 - 110Turner RS, Kuo JFEditors: Kuo, JF.CRC Press, Boca Raton1985
Neurobiology: Molecular Biological Approaches to Understanding Neuronal Function and Development
Chapter: Developmental Studies of Phospholipid Calcium-Dependent and S-100-Modulated Protein Phosphorylation Systems in Brain
Page 101 - 111Turner RS, Qi DF, Kuo JFEditors: O'Lague P.Alan R. Liss, Inc., New York1985
Calcium and Cell Function
Chapter: Phospholipid-Sensitive Calcium-Dependent Protein Phosphorylation
Page 33 - 66Schatzman RC, Turner RS, Kuo JFEditors: Cheung, WY.Academic Press, Orlando1984
Join now to see all

Grant Support

Alzheimer's Clinical Trials ConsortiumNational Institute on Aging2023–2028
Using digital signals from credit data for early detection of Alzheimer's disease and related dementiasNational Institute on Aging2023–2027
A randomized, double blind, placebo controlled, parallel group trial to evaluate the safety and efficacy of CT1812 in early Alzheimer's disease over 18 months (START)National Institute on Aging2020–2025
Metformin in Alzheimer's dementia Prevention (MAP)National Institute on Aging2019–2024
The AHEAD A45 combination anti-amyloid therapy for preclinical Alzheimer's diseaseNational Institute on Aging2018–2024
A Seamless Phase 2A-B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PQ912 in Patients with Early Alzheimer’s DiseaseNational Institute on Aging2020–2023
Early Onset AD Consortium - the LEADS studyNational Institute on Aging2018–2023
AHEAD: The A3 Study: Ante-amyloid prevention of Alzheimer's diseaseNational Institute on Aging2016–2023

Committees

Site PI, Steering Committee member, Alzheimer's Clinical Trials Consortium, University of Southern California, San Diego 2015 - Present
Associate Editor, Reviewer, Frontiers in Neurology, Frontiers in Psychiatry, Frontiers in Neuroscience - Neurodegeneration 2009 - Present
Site PI, Steering Committee Member, past Project PI, Alzheimer's Disease Cooperative Study, University of California, San Diego 2005 - Present
Editorial Board Member, Reviewer, Aging, Neuropsychology, and Cognition 2000 - Present

Professional Memberships

American Academy of Neurology - AAN
Fellow
American Neurological Association
Fellow
International Society to Advance Alzheimer's Research and Treatment (ISTAART)
Member